have been shownto reduce tissue sorbitol levels and to improve diabetic complications.2) In the preceding papers, we reported the isolation,3) structure elucidation and total synthesis of WF-3681, a novel aldose reductase inhibitor isolated from a cultured filtrate of Chaetomella raphigera.4) Moreover, several derivatives of WF-3681 were synthesized and their structure-aldose reductase inhibitory activity relationship was also discussed.5) In this paper, we report the effects of WF-3681and its derivatives on sorbitol accumulation in the sciatic nerve of diabetic rats. Seven-weeks-old Sprague-Dawley male rats were modified method of Clements et al.6) Briefly, the made diabetic by a single ip injection ofstreptozoto-sciatic nerves were homogenized in I n perchloric cin with a dose of 75mg/kg. After 7 days of the acid in a glass homogenizer and centrifuged at streptozotocin injection, plasma glucose levels of all 900 x g for 10minutes at 4°C. The supernatants rats were analyzed by sampling blood from the tail were neutralized with 5 MK2CO3and centrifuged. vein. The rats with a plasma glucose level of above Sorbitol concentration in the supernatants was 400 mg/deciliter were grouped at random, so that the determined by an enzymatic method using sorbitol mean body weights and blood glucose levels of each dehydrogenase (SDH). The reaction mixture congroup were not significantly different. Each of the tained glycine buffer 50mM (pH 9.6), MgCl2 2mM, derivatives5* ofWF-3681 suspended in 0.5% methyl NAD+4mM, SDH0.7u and 0.6ml of the sample cellulose was given to rats orally once daily from in a total volume of 2.0ml. Sorbitol levels in the day 8 to 12. At day 12, the animals were killed and extract were determined fluorometrically. The sciatic nerve were separated from the animals. The change of fluorescence due to NADH after innerves were weighed immediately and frozen at cubation for 30minutes at 37°C was monitored -20°C until determination of sorbitol levels. by a fluorometer (excitation; 360nm, emission; Sorbitol was measured enzymatically by the 460nm).
WF-3681 and its derivatives which were obtained by addition ofphenyl (A), hydroxy (B) and carboxy (C) groups5* as depicted in Fig. 1 were evaluated in this model. Inhibitory effects of WF-3681 and its derivatives at a dose of 32mg/kg on sorbitol accumulation in the sciatic nerve of diabetic rats are shown in Tables 1, 2 and 3 . The data were expressed as inhibitory percent. Each value was calculated as follows: Inhibition (%)=(DS-IS)/(DS-NS) x 100, where DS and NS are sorbitol levels in the nerve of diabetic and normal control rats, respectively and IS is that of diabetic rats treated with each compound. In vitro aldose reductase inhibitory activities of these compounds were also shownas reference.
The effects of WF-3681 and 3-aryl derivatives on the sorbitol accumulation in the sciatic nerve of diabetic rats are shown in Table 1 . WF-3681 showed 23% inhibition on sorbitol accumulation but the value was not statistically significant.
The 3-aryl derivatives tested did not inhibit the sorbitol accumulation, except for compound ll. Previously, the introduction of lypophilic substituents at the 4-position of the benzene ring, compounds 2, 6 and 7, enhanced the in vitro activity by about 5-fold as compared with the mother compound5)but they
were not effective in this model. In vivo efficacy of each compoundmight depend on its pharmacokinetic property. Table 2 shows the effects of the alkylether derivatives in this model. Compounds 14, 15, 16, 18 and 19 were more effective than the parent compound. The carbon chain length of these compoundsis important for activity. The effects of SEPT. 1990 the alterations of the carboxylic acid are shown in 
